[{"orgOrder":0,"company":"CellProthera","sponsor":"BioCardia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"ProtheraCytes","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CellProthera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CellProthera \/ BioCardia","highestDevelopmentStatusID":"8","companyTruncated":"CellProthera \/ BioCardia"}]

Find Clinical Drug Pipeline Developments & Deals by CellProthera

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO CEO & Investor
                          Not Confirmed
                          BIO CEO & Investor
                          Not Confirmed

                          Details : The collaboration aims to support the advancement of the mid-stage clinical trial product ProtheraCytes, which is being evaluated for the treatment of acute myocardial infarction led by CellProthera.

                          Product Name : ProtheraCytes

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 08, 2024

                          Lead Product(s) : ProtheraCytes

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : BioCardia

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank